Design & analysis of clinical trials for economic evaluation & reimbursement : an applied approach using SAS & STATA /: an applied approach using SAS & STATA. (2015)

• Record Type: Book
• Further Information: Note: Iftekhar Khan.
• Authors: Khan, Iftekhar
• Contents: Introduction to Economic Evaluation ; Health Economics, Pharmacoeconomics, and Economic Evaluation; Important Concepts in Economic Evaluation; Health Economic Evaluation and Drug Development; Efficacy, Effectiveness and Efficiency; When Is a Pharmacoeconomic Hypothesis Possible?; Exercises; ; Health Economic Evaluation Concepts ; Incremental Cost-Effectiveness Ratio (ICER); Incremental INMB; The Concept of Dominance; Types of Economic Evaluation; Statistical versus Health Economic Models; Exercises; Appendix SAS/STATA Code; ; Designing Cost-Effectiveness into a Clinical Trial ; Reasons for Collecting Economic Data in a Clinical Trial; Planning a Health Economic Evaluation in a Clinical Trial; Clinical Trial Design Issues in an Economic Evaluation; Integrating Economic Evaluation in a Clinical Trial: Considerations; CRF Design and Data Management Issues; Case Study of a Lung Cancer Trial with an Economic; Evaluation; Exercises; Appendix: SAS/STATA; ; Analysing Cost Data Collected in a Clinical Trial ; Collecting and Measuring Costs for the Case Report Form; Types of Costs; Other Concepts in Costs: Time Horizon and Discounting; CRFs for Collecting Resource Use Data in Clinical Trials; Statistical Modelling of Cost Data; Using Generalised Linear Models to Analyse Cost Data; Models for Skewed Distributions Outside the GLM Family of Distributions; Summary of Modelling Approaches; Handling Censored and Missing Costs; Strategies for Avoiding Missing Resource Data; Strategies for Analysing Cost Data When Data Are Missing or Censored; Imputation Methods; Censored Cost Data; Method of Lin et al. (1997); Summary and Conclusion; Exercises; Appendix: SAS/STATA Code; ; Quality of Life in Economic Evaluation ; Quality of Life in Clinical Trials versus Quality of Life for Economic Evaluation; Disease-Specific and Generic Measures of HRQoL; HRQoL Instruments Used for the Purposes of Economic Evaluation; When HRQoL Data Have Not Been Collected in a Clinical Trial; HRQoL Metrics for Use in Economic Evaluations; Are Utility Measures Sensitive Enough for Detecting Treatment Differences?; Exercises; Appendix 5A SAS/STATA Code; Technical Appendix: Beta Binomial Technical Details; Technical Appendix: Technical Summary of the GLM; ; Modelling in Economic Evaluation ; Introduction to Modelling: Statistical versus Economic Modelling; Decision Tree Models; Markov Modelling/Cohort Simulation; Analysis of Patient-Level Data; Patient-Level Simulation; Other Issues in Modelling; Exercises; Appendix: SAS/STATA Code; ; Sensitivity Analyses ; Introduction to Sensitivity Analysis; One-Way Sensitivity Analysis; Two-Way Sensitivity Analysis; PSA; Bayesian Sensitivity Analyses; Issues in Interpreting and Reporting Results from Sensitivity Analysis; Exercises; Appendix: SAS/STATA Code; ; Sample Size and Value of Information for Cost-Effectiveness Trials ; Introduction; Sample Sizes for Cost-Effectiveness; Sample Size Methods for Efficacy; Sample Size Formulae for Cost-Effectiveness: Examples; Factors Affecting Sample Sizes; The Minimum Sample Size to Establish Cost-Effectiveness; Bayesian Sample Size Approach; The Normality Assumption; Obtaining the Necessary Data and Tools for Calculating; Sample Size; Value of Information; Exercises for Chapter 8; Appendix 8A SAS/STATA Code; Technical Appendix 8B Derivation of Sample Size Formula; Technical Appendix 8C Comparison with Briggs and Tambour’s (2001) Approach; ; Mixed Treatment Comparisons, Evidence Synthesis ; Introduction; MTCs; Meta-Analysis; Exercises; Appendix: SAS/STATA Code; ; Cost-Effectiveness Analyses of Cancer Trials ; Introduction; Modelling Patient-Level Data from Cancer Trials for Cost-; Effectiveness; Flexible Parametric Survival Models; Modelling Survival Data Using a Flexible Parametric Model; Cost-Effectiveness of Lenalidomide; Transition Probabilities and Survival Rates; Handling Crossover (Treatment Switching) in Cancer Trials; Landmark Analysis and Presenting Survival Data by Tumour Response; Exercises; Appendix: SAS/STATA Code; ; The Reimbursement Environment ; Regulatory Requirements for Clinical Efficacy versus Payer Requirements for Value; Reimbursement and Payer Evidence Requirements across Different Countries; Market Access and Strategy; Value-Based Pricing; Submissions for Payer Evidence; Further Areas for Research; Exercises ; ; References; ; Bibliography; ; Index
• Edition: 1st
• Publisher Details: Boca Raton : Chapman & Hall/CRC
• Publication Date: 2015
• Extent: 1 online resource, illustrations (black and white)
• Subjects: 338.473621; Medical economics; Clinical trials -- Economic aspects
• Languages: English
• ISBNs: 9781466505483
• Related ISBNs: 9781466505476
• Notes: Note: Includes bibliographical references and index.; Note: Description based on CIP data; item not viewed.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.